JP2017525698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525698A5 JP2017525698A5 JP2017508075A JP2017508075A JP2017525698A5 JP 2017525698 A5 JP2017525698 A5 JP 2017525698A5 JP 2017508075 A JP2017508075 A JP 2017508075A JP 2017508075 A JP2017508075 A JP 2017508075A JP 2017525698 A5 JP2017525698 A5 JP 2017525698A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- residues
- fusion protein
- sirpα
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 37
- 102000018358 immunoglobulin Human genes 0.000 claims 37
- 108020001507 fusion proteins Proteins 0.000 claims 29
- 102000037865 fusion proteins Human genes 0.000 claims 29
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 28
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 28
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 210000003743 erythrocyte Anatomy 0.000 claims 8
- 229960005395 cetuximab Drugs 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 238000012986 modification Methods 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 102220470105 Amidophosphoribosyltransferase_Q37H_mutation Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010058590 CD47 Antigen Proteins 0.000 claims 1
- 102000006355 CD47 Antigen Human genes 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 210000000270 basal cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 229950002140 futuximab Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229950008001 matuzumab Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 229950010203 nimotuzumab Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102220266399 rs1555186817 Human genes 0.000 claims 1
- 102220024927 rs199472833 Human genes 0.000 claims 1
- 102200145334 rs2274084 Human genes 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462038196P | 2014-08-15 | 2014-08-15 | |
| US62/038,196 | 2014-08-15 | ||
| PCT/EP2015/068798 WO2016024021A1 (en) | 2014-08-15 | 2015-08-14 | Sirp-alpha immunoglobulin fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525698A JP2017525698A (ja) | 2017-09-07 |
| JP2017525698A5 true JP2017525698A5 (https=) | 2018-09-20 |
| JP6764858B2 JP6764858B2 (ja) | 2020-10-07 |
Family
ID=53872055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017508075A Expired - Fee Related JP6764858B2 (ja) | 2014-08-15 | 2015-08-14 | Ｓｉｒｐ−アルファ免疫グロブリン融合タンパク質 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11021694B2 (https=) |
| EP (2) | EP3180363B2 (https=) |
| JP (1) | JP6764858B2 (https=) |
| KR (1) | KR20170036796A (https=) |
| CN (1) | CN107108748A (https=) |
| AU (1) | AU2015303135B2 (https=) |
| BR (1) | BR112017002646A2 (https=) |
| CA (1) | CA2956126A1 (https=) |
| DK (1) | DK3180363T3 (https=) |
| ES (1) | ES2751915T5 (https=) |
| HR (1) | HRP20191872T1 (https=) |
| HU (1) | HUE046661T2 (https=) |
| IL (1) | IL250622B2 (https=) |
| LT (1) | LT3180363T (https=) |
| MX (1) | MX377196B (https=) |
| PL (1) | PL3180363T3 (https=) |
| PT (1) | PT3180363T (https=) |
| RU (1) | RU2017108203A (https=) |
| SG (1) | SG11201701189TA (https=) |
| SI (1) | SI3180363T1 (https=) |
| WO (1) | WO2016024021A1 (https=) |
| ZA (1) | ZA201701810B (https=) |
Families Citing this family (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2914814T3 (es) | 2012-12-17 | 2022-06-16 | Pf Argentum Ip Holdings Llc | Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc |
| AU2014227638A1 (en) * | 2013-03-15 | 2015-09-17 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| HUE046661T2 (hu) | 2014-08-15 | 2020-03-30 | Merck Patent Gmbh | SIRP-alfa immunglobulin fúziós proteinek |
| CA2978186A1 (en) * | 2015-03-05 | 2016-09-09 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| WO2017027422A1 (en) | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| RU2766200C1 (ru) | 2015-10-01 | 2022-02-09 | Хит Байолоджикс, Инк. | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков |
| CN107149682B (zh) * | 2016-03-04 | 2022-01-04 | 复旦大学 | 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法 |
| US11649284B2 (en) * | 2016-04-18 | 2023-05-16 | Baylor College Of Medicine | Cancer gene therapy targeting CD47 |
| US11560433B2 (en) | 2016-05-27 | 2023-01-24 | Albert Einstein College Of Medicine | Methods of treatment by targeting VCAM1 and MAEA |
| CN107459578B (zh) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
| US20190153095A1 (en) * | 2016-07-05 | 2019-05-23 | National University Corporation Kobe University | Antitumor Agent |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| CN109790215B (zh) | 2016-09-29 | 2023-06-30 | 北京韩美药品有限公司 | 异源二聚体免疫球蛋白构建体和其制备方法 |
| BR112019008010A2 (pt) | 2016-10-20 | 2019-07-09 | I-Mab | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CN106519036B (zh) * | 2016-11-04 | 2019-06-11 | 新乡医学院 | 抗cd47和egfr的双功能蛋白及其制备方法与应用 |
| JP7031810B2 (ja) | 2016-11-18 | 2022-03-08 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド | 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法 |
| CN108220228A (zh) * | 2016-12-09 | 2018-06-29 | 上海迈泰君奥生物技术有限公司 | 无血清细胞培养基及高效表达重组蛋白质的方法 |
| LT3565579T (lt) | 2017-01-05 | 2023-09-11 | Kahr Medical Ltd. | Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| WO2018127918A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirp alpha-cd70 fusion protein and methods of use thereof |
| PT3565828T (pt) | 2017-01-05 | 2022-02-08 | Kahr Medical Ltd | Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização |
| US11192933B2 (en) | 2017-02-27 | 2021-12-07 | Shattuck Labs, Inc. | VSIG8-based chimeric proteins |
| MX2019009812A (es) | 2017-02-27 | 2019-10-14 | Shattuck Labs Inc | Proteinas quimericas basadas en tigit y light. |
| KR20190124247A (ko) | 2017-02-27 | 2019-11-04 | 샤턱 랩스 인코포레이티드 | Csf1r-기반 키메라 단백질 |
| CN108623689B (zh) * | 2017-03-15 | 2020-10-16 | 宜明昂科生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制备方法和用途 |
| AU2018236461B2 (en) | 2017-03-17 | 2025-03-27 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| AU2018264321B2 (en) * | 2017-05-08 | 2025-03-06 | Shanghai Jmt-Bio Technology Co., Ltd. | Bispecific recombinant protein and use thereof |
| CN111448323B (zh) * | 2017-06-07 | 2023-12-01 | 长源赋能(上海)生命科技有限公司 | 精确制导的多功能治疗抗体 |
| JP7262440B2 (ja) | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｃｄ４７抗体及びその使用 |
| TW201925230A (zh) * | 2017-08-30 | 2019-07-01 | 丹麥商賽門弗鎮公司 | 以抗egfr療法治療癌症的組成物及方法 |
| CN111051350B (zh) * | 2017-09-07 | 2022-11-01 | 苏州丁孚靶点生物技术有限公司 | 包含信号调节蛋白α的免疫缀合物 |
| KR20190037164A (ko) * | 2017-09-28 | 2019-04-05 | 한국과학기술연구원 | 신규 암 치료용 조성물 |
| JP2020536967A (ja) * | 2017-10-12 | 2020-12-17 | イミュノウェイク インコーポレイテッド | Ｖｅｇｆｒ−抗体軽鎖融合タンパク質 |
| WO2019080883A1 (en) * | 2017-10-26 | 2019-05-02 | Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. | NOVEL RECOMBINANT FUSION PROTEINS, PREPARATION THEREOF AND USE THEREOF |
| KR102366853B1 (ko) * | 2017-11-10 | 2022-02-23 | 아이-맵 바이오파마 유에스 리미티드 | Cd47 항체 및 사이토카인을 포함하는 융합 단백질 |
| WO2019095358A1 (zh) * | 2017-11-20 | 2019-05-23 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
| WO2019109876A1 (zh) | 2017-12-04 | 2019-06-13 | 北京韩美药品有限公司 | 抗pd‐l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| WO2019109357A1 (zh) | 2017-12-08 | 2019-06-13 | 杭州翰思生物医药有限公司 | 抗pd-1/cd47的双特异性抗体及其应用 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| US20210040219A1 (en) * | 2018-03-13 | 2021-02-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by egfr antibody |
| MX2020009774A (es) | 2018-03-21 | 2020-10-08 | Alx Oncology Inc | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. |
| CN110386984B (zh) * | 2018-04-17 | 2022-04-22 | 杭州尚健生物技术有限公司 | 结合cd47蛋白的融合蛋白及其应用 |
| CN108794641A (zh) * | 2018-07-04 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种针对EGFRvIII的多功能融合蛋白及其应用 |
| US12134638B2 (en) | 2018-07-11 | 2024-11-05 | Kahr Medical Ltd. | SIRPalpha-4-1BBL variant fusion protein and methods of use thereof |
| KR20210044221A (ko) | 2018-07-11 | 2021-04-22 | 카 메디컬 리미티드 | Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법 |
| EP3833690B1 (en) * | 2018-08-08 | 2024-03-27 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Recombinant bifunctional protein targeting cd47 and her2 |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| JP7557920B2 (ja) | 2018-09-04 | 2024-09-30 | ファイザー・インク | 疾患治療のためのｐａｒｐ阻害と組み合わせたｃｄ４７遮断 |
| CN109535258A (zh) * | 2018-10-26 | 2019-03-29 | 上海科弈药业科技有限公司 | 一种针对Her2+肿瘤的多功能融合蛋白及其应用 |
| KR20210096612A (ko) * | 2018-10-29 | 2021-08-05 | 티가티엑스, 인크. | IgA 항체 구축물을 포함하는 조성물 및 방법 |
| CN111303293B (zh) * | 2018-11-14 | 2022-08-30 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| CN113271972B (zh) * | 2018-11-14 | 2025-06-17 | Jn生物科学有限责任公司 | 用于替代IVIG的多聚体杂交Fc蛋白 |
| CA3118966A1 (en) * | 2018-11-15 | 2020-05-22 | Byondis B.V. | Humanized anti-sirpa antibodies |
| CN109517054B (zh) * | 2018-12-04 | 2022-04-08 | 江苏东抗生物医药科技有限公司 | SIRPα变体或其融合蛋白及其应用 |
| CN109535263B (zh) * | 2018-12-04 | 2022-06-17 | 江苏东抗生物医药科技有限公司 | SIRPα突变体及其融合蛋白 |
| AU2019409805A1 (en) * | 2018-12-21 | 2021-07-22 | Ose Immunotherapeutics | Bifunctional anti-PD-1/SIRPA molecule |
| WO2020177733A1 (zh) * | 2019-03-06 | 2020-09-10 | 江苏恒瑞医药股份有限公司 | 双功能融合蛋白及其医药用途 |
| CN111763261B (zh) * | 2019-04-02 | 2022-08-09 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| TW202045550A (zh) | 2019-04-05 | 2020-12-16 | 美商西建公司 | 腫瘤選擇性結合cd47之抗體之工程 |
| BR112021024003A2 (pt) | 2019-05-31 | 2022-04-19 | Alx Oncology Inc | Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico |
| KR20220034117A (ko) * | 2019-06-14 | 2022-03-17 | 더 스크립스 리서치 인스티튜트 | 면역 관문 차단 이중특이성 분자 |
| CN114072426B (zh) * | 2019-07-08 | 2024-01-26 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗pd-1双特异抗体及其制备方法和应用 |
| CN114761041A (zh) | 2019-07-16 | 2022-07-15 | 吉利德科学公司 | Hiv疫苗及其制备和使用方法 |
| WO2021013215A1 (zh) * | 2019-07-23 | 2021-01-28 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗lag-3双特异抗体及其制备方法和应用 |
| EP4021485A1 (en) * | 2019-08-28 | 2022-07-06 | King's College London | B cell targeted parallel car (pcar) therapeutic agents |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| KR20220091576A (ko) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
| CN115038718B (zh) * | 2019-11-08 | 2024-07-02 | 山东先声生物制药有限公司 | 抗人程序性死亡配体-1（pd-l1）的抗体及其用途 |
| AU2020394204A1 (en) | 2019-11-27 | 2022-06-02 | ALX Oncology Inc. | Combination therapies for treating cancer |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| KR20260017503A (ko) | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| CN111808183B (zh) * | 2020-07-25 | 2022-07-08 | 北京吉尔麦迪生物医药科技有限公司 | 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白 |
| JP7814759B2 (ja) * | 2020-09-17 | 2026-02-17 | 上海霖羲致企業管理有限公司 | 二重特異性組換えタンパク質及びその使用 |
| JP2023545983A (ja) * | 2020-10-07 | 2023-11-01 | セルジーン コーポレイション | リンパ系悪性腫瘍状態の二重特異性抗体治療 |
| WO2022120286A1 (en) * | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| CN112708675A (zh) * | 2020-12-25 | 2021-04-27 | 中山大学肿瘤防治中心 | 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用 |
| CN112656941A (zh) * | 2021-01-20 | 2021-04-16 | 福建医科大学附属协和医院 | 抗cd47单克隆抗体在制备抗阿霉素耐药的急性淋巴细胞白血病细胞的药物中应用 |
| KR20230157388A (ko) | 2021-03-12 | 2023-11-16 | 멘두스 비.브이. | 백신접종의 방법 및 cd47 차단의 용도 |
| EP4320156A1 (en) * | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20230016152A (ko) * | 2021-07-19 | 2023-02-01 | 주식회사유한양행 | Sirp-alpha 변이체 및 이의 용도 |
| CN120329453A (zh) * | 2021-07-19 | 2025-07-18 | 百奥泰生物制药股份有限公司 | 基于Luciferase报告基因系统的重组嵌合膜蛋白及其应用 |
| CN113956363B (zh) * | 2021-10-13 | 2023-03-31 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向cd47和cd24的重组融合蛋白及其制备和用途 |
| WO2023072217A1 (en) * | 2021-10-28 | 2023-05-04 | Guangzhou Lintonpharm Co., Ltd. | Fusion proteins targeting cd3 and cd47 |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| US20250367255A1 (en) | 2021-11-08 | 2025-12-04 | Pfizer Inc. | Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents |
| WO2023121887A2 (en) * | 2021-12-21 | 2023-06-29 | Fbd Biologics Limited | ENGINEERED SIRPα VARIANTS AND METHODS OF USE THEREOF |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| CN118401564A (zh) * | 2022-01-18 | 2024-07-26 | Fbd生物制品有限公司 | 靶向cd47/pd-l1的蛋白质复合物和其使用方法 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| WO2023183890A1 (en) * | 2022-03-24 | 2023-09-28 | Bitterroot Bio, Inc. | Multivalent sirp-alpha fusion polypeptides |
| IL315706A (en) | 2022-03-24 | 2024-11-01 | Bitterroot Bio Inc | Sirp-alpha fusion polypeptides with modified fc domains |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| KR20240162568A (ko) * | 2022-03-25 | 2024-11-15 | 우시 바이올로직스 아일랜드 리미티드 | 항-her2/항-cd47 분자 및 이의 용도 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2023263628A1 (en) * | 2022-05-06 | 2024-12-19 | Biosion Inc. | Recombinant fusion protein targeting cd40 and cd47 |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11807689B1 (en) * | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| CN116041470B (zh) * | 2022-08-04 | 2024-10-22 | 四川大学华西医院 | 具有高亲和力结合肿瘤细胞cd47的细胞膜材料及其制备方法和应用 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4592316A1 (en) * | 2022-09-23 | 2025-07-30 | Lindis Biotech GmbH | Isolated antigen-binding protein and use thereof |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN118546255A (zh) * | 2023-02-24 | 2024-08-27 | 恒翼生物医药(上海)股份有限公司 | 一种靶向αvβ3和CD47的双功能融合蛋白以及其应用 |
| WO2024193635A1 (en) * | 2023-03-22 | 2024-09-26 | Wangzhi LI | Sirp variants and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| KR20260019369A (ko) | 2023-05-31 | 2026-02-10 | 에프비디 바이올로직스 리미티드 | Cd47/pd-l1-표적화 단백질 복합체 및 그의 사용 방법 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025247303A1 (zh) * | 2024-05-30 | 2025-12-04 | 上海艾乐晞生物科技有限公司 | 具有pH依赖结合活性的人信号调节蛋白α突变体及其应用 |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9930706D0 (en) | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| US20090191202A1 (en) | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| WO2007062037A2 (en) | 2005-11-21 | 2007-05-31 | Laboratoires Serono Sa | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| US20100239578A1 (en) | 2007-10-11 | 2010-09-23 | University Health Network | Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| US20110237498A1 (en) | 2008-12-19 | 2011-09-29 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| PL2995315T3 (pl) | 2009-05-15 | 2024-04-22 | University Health Network | Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47 |
| EP2477648B1 (en) | 2009-09-15 | 2022-07-20 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| SI2804617T1 (sl) | 2012-01-17 | 2020-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Visokoafinitetni SIRP-alfa reagenti |
| ES2914814T3 (es) | 2012-12-17 | 2022-06-16 | Pf Argentum Ip Holdings Llc | Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc |
| US9873747B2 (en) * | 2013-01-31 | 2018-01-23 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| AU2014227638A1 (en) | 2013-03-15 | 2015-09-17 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| KR102314088B1 (ko) * | 2014-03-24 | 2021-10-15 | 이뮨원코 바이오파마슈티컬즈 (상하이) 컴퍼니 리미티드 | 새로운 이중 기능성의 재조합 융합 단백질, 이의 제조 방법 및 용도 |
| US10087257B2 (en) | 2014-08-08 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | SIRP alpha-antibody fusion proteins |
| HUE046661T2 (hu) | 2014-08-15 | 2020-03-30 | Merck Patent Gmbh | SIRP-alfa immunglobulin fúziós proteinek |
-
2015
- 2015-08-14 HU HUE15750744A patent/HUE046661T2/hu unknown
- 2015-08-14 WO PCT/EP2015/068798 patent/WO2016024021A1/en not_active Ceased
- 2015-08-14 PL PL15750744T patent/PL3180363T3/pl unknown
- 2015-08-14 US US14/827,003 patent/US11021694B2/en not_active Expired - Fee Related
- 2015-08-14 CA CA2956126A patent/CA2956126A1/en active Pending
- 2015-08-14 LT LT15750744T patent/LT3180363T/lt unknown
- 2015-08-14 EP EP15750744.3A patent/EP3180363B2/en active Active
- 2015-08-14 MX MX2017001712A patent/MX377196B/es active IP Right Grant
- 2015-08-14 SI SI201530975T patent/SI3180363T1/sl unknown
- 2015-08-14 BR BR112017002646-5A patent/BR112017002646A2/pt not_active IP Right Cessation
- 2015-08-14 SG SG11201701189TA patent/SG11201701189TA/en unknown
- 2015-08-14 AU AU2015303135A patent/AU2015303135B2/en not_active Ceased
- 2015-08-14 KR KR1020177006711A patent/KR20170036796A/ko not_active Ceased
- 2015-08-14 PT PT157507443T patent/PT3180363T/pt unknown
- 2015-08-14 EP EP19198866.6A patent/EP3643727A1/en not_active Withdrawn
- 2015-08-14 RU RU2017108203A patent/RU2017108203A/ru not_active Application Discontinuation
- 2015-08-14 HR HRP20191872TT patent/HRP20191872T1/hr unknown
- 2015-08-14 CN CN201580054385.2A patent/CN107108748A/zh active Pending
- 2015-08-14 ES ES15750744T patent/ES2751915T5/es active Active
- 2015-08-14 JP JP2017508075A patent/JP6764858B2/ja not_active Expired - Fee Related
- 2015-08-14 DK DK15750744T patent/DK3180363T3/da active
-
2017
- 2017-02-15 IL IL250622A patent/IL250622B2/en unknown
- 2017-03-14 ZA ZA2017/01810A patent/ZA201701810B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525698A5 (https=) | ||
| RU2017108203A (ru) | Слитые белки sirp-альфа с иммуноглобулином | |
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2020063262A5 (https=) | ||
| ES2773504T3 (es) | Nuevo polipéptido que tiene afinidad por PD-L1 | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2017506217A5 (https=) | ||
| FI3459597T3 (fi) | Yksiketjuinen vasta-aine ctla4:lle ja siitä johdettu proteiini | |
| JP2018508214A5 (https=) | ||
| JP2014518615A5 (https=) | ||
| JP2019532619A5 (https=) | ||
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| JP2019524693A5 (https=) | ||
| FI3579848T3 (fi) | Monispesifisiä sitovia proteiineja luonnollisten tappajasolujen aktivointiin ja niiden terapeuttisia käyttöjä syövän hoitoon | |
| JP2020506971A5 (https=) | ||
| JP2012523848A5 (https=) | ||
| JP2018527919A5 (https=) | ||
| JP2018517431A5 (https=) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2017527274A5 (https=) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| JP2018503380A5 (https=) | ||
| JP2017520575A5 (https=) | ||
| HRP20170462T1 (hr) | Protutijela za epidermalni receptor 3 faktora rasta (her3) | |
| JP2017504578A5 (https=) |